WO2010041827A3 - NF-κB INHIBITOR CONTAINING ARH1 PROTEIN OR GENE ENCODING THE SAME - Google Patents

NF-κB INHIBITOR CONTAINING ARH1 PROTEIN OR GENE ENCODING THE SAME Download PDF

Info

Publication number
WO2010041827A3
WO2010041827A3 PCT/KR2009/005239 KR2009005239W WO2010041827A3 WO 2010041827 A3 WO2010041827 A3 WO 2010041827A3 KR 2009005239 W KR2009005239 W KR 2009005239W WO 2010041827 A3 WO2010041827 A3 WO 2010041827A3
Authority
WO
WIPO (PCT)
Prior art keywords
same
gene encoding
inhibitor containing
arh1 protein
arh1
Prior art date
Application number
PCT/KR2009/005239
Other languages
French (fr)
Other versions
WO2010041827A2 (en
Inventor
Seung Bae Rho
Sang Yoon Park
Original Assignee
National Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Cancer Center filed Critical National Cancer Center
Publication of WO2010041827A2 publication Critical patent/WO2010041827A2/en
Publication of WO2010041827A3 publication Critical patent/WO2010041827A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to novel uses of ARH1 protein or a gene encoding the same, more particularly, to an NF-κB inhibitor comprising the ARH1 protein or the gene encoding the same as an active ingredient and a composition for the treatment of angiogenesis-related diseases, inflammatory diseases, autoimmune diseases, or viral diseases, comprising the inhibitor.
PCT/KR2009/005239 2008-10-08 2009-09-15 NF-κB INHIBITOR CONTAINING ARH1 PROTEIN OR GENE ENCODING THE SAME WO2010041827A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020080098737A KR101071305B1 (en) 2008-10-08 2008-10-08 NF-κB Inhibitor containing ARH1 protein or gene encoding the same
KR10-2008-0098737 2008-10-08

Publications (2)

Publication Number Publication Date
WO2010041827A2 WO2010041827A2 (en) 2010-04-15
WO2010041827A3 true WO2010041827A3 (en) 2010-06-24

Family

ID=42101055

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/005239 WO2010041827A2 (en) 2008-10-08 2009-09-15 NF-κB INHIBITOR CONTAINING ARH1 PROTEIN OR GENE ENCODING THE SAME

Country Status (2)

Country Link
KR (1) KR101071305B1 (en)
WO (1) WO2010041827A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ589444A (en) 2008-05-28 2013-03-28 Validus Biopharma Inc NON-HORMONAL STEROID MODULATORS OF NF-Kappa B FOR TREATMENT OF DISEASE
WO2017004205A1 (en) 2015-06-29 2017-01-05 Reveragen Biopharma, Inc. NON-HORMONAL STEROID MODULATORS OF NF-κB FOR TREATMENT OF DISEASE
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824487A (en) * 1993-04-23 1998-10-20 Sloan-Kettering Institute For Cancer Research Method for screening for targets for anti-inflammatory or anti-allergic agents
US20020138880A1 (en) * 1995-05-01 2002-09-26 Richard Clague Gardner Aluminium resistance gene
US20080207555A1 (en) * 2005-09-13 2008-08-28 The Govt. Of Usa As Represented By The Secretary Of The Dept. Of Health And Human Services Hydrolase and methods for its use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795306B2 (en) * 2006-03-03 2010-09-14 Inderjit Kumar Dev Triterpene derivatives for the treatment of cancer and inflammatory disease by inhibition of NF-κB

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824487A (en) * 1993-04-23 1998-10-20 Sloan-Kettering Institute For Cancer Research Method for screening for targets for anti-inflammatory or anti-allergic agents
US20020138880A1 (en) * 1995-05-01 2002-09-26 Richard Clague Gardner Aluminium resistance gene
US20080207555A1 (en) * 2005-09-13 2008-08-28 The Govt. Of Usa As Represented By The Secretary Of The Dept. Of Health And Human Services Hydrolase and methods for its use

Also Published As

Publication number Publication date
KR20100039676A (en) 2010-04-16
WO2010041827A2 (en) 2010-04-15
KR101071305B1 (en) 2011-10-07

Similar Documents

Publication Publication Date Title
WO2009155001A3 (en) Wnt protein signalling inhibitors
MY146969A (en) Dpp iv inhibitor formulations
WO2006117217A3 (en) Novel use of spiegelmers
WO2009043889A3 (en) Oxadiazole derivatives
WO2008085221A3 (en) Therapeutic use of cd31 expressing cells
WO2008033562A3 (en) Kinase inhibitor compounds
WO2010151799A3 (en) Compounds for modulating rna binding proteins and uses therefor
WO2011072099A3 (en) Compositions and methods comprising protease variants
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2011002808A8 (en) Hcv protease inhibitors and uses thereof
WO2009156462A3 (en) Organic compounds
WO2008067219A3 (en) Quinazolinone modulators of tgr5
WO2010151797A3 (en) Compounds for modulating rna binding proteins and uses therefor
WO2008118332A3 (en) Hydrazido-peptides as inhibitors of hcv ns3-protease
WO2010049454A3 (en) Antimicrobial composition from copepods
WO2010048358A3 (en) Ethoxyphenylmethyl inhibitors of sglt2
WO2009061841A3 (en) Modified polynucleotides as antidotes to antisense compounds
WO2010147830A3 (en) Aminothiazole modulators of beta-3-adrenoreceptor
WO2009115084A3 (en) Pyrrolopyrimidine derivatives, and use thereof
WO2010118291A3 (en) Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
WO2008061108A3 (en) Phthalazine derivatives
WO2011069037A3 (en) Stabilization and storage of biological pharmaceutical compositions
WO2010142551A8 (en) Amino acid sequences directed against receptors to cytokines belonging to the il-17 family
WO2009125409A3 (en) Fatty acid amides and uses thereof
WO2008095622A3 (en) SECRETED LUCIFERASE MLuc7 AND USE THEREOF

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09819334

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09819334

Country of ref document: EP

Kind code of ref document: A2